SAB Biotherapeutics (SABS) Change in Accured Expenses (2020 - 2026)

SAB Biotherapeutics has reported Change in Accured Expenses for 7 years, with the latest figure at -$1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 304.94% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$836515.0 (down 189.77% YoY), and the FY2025 full-year result was $941524.0, up 176.48% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.2 million, down from -$394856.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $1.9 million in Q3 2024, with the low at -$2.0 million in Q2 2022.
• Historically, Change in Accured Expenses has averaged -$337477.3 across 5 years, with a median of -$394856.0 in 2025.
• Annual changes were most pronounced in 2025 — Change in Accured Expenses jumped 1661.16% — and 2026, when it plunged 304.94%.
• SAB Biotherapeutics' Change in Accured Expenses stood at -$320231.0 in 2022, then surged by 538.06% to $1.4 million in 2023, then slumped by 202.66% to -$1.4 million in 2024, then surged by 72.58% to -$394856.0 in 2025, then slumped by 202.63% to -$1.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.2 million (Q1 2026), -$394856.0 (Q4 2025), and -$287490.0 (Q3 2025), per Business Quant data.